ISL
EBS icon

Ingalls & Snyder LLC’s Emergent Biosolutions EBS Stock Holding History

Ingalls & Snyder LLC’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,369
Closed -$212K – 462
2021
Q2 		$212K Buy
3,369
+902
+37% +$57.9K 0.01% 434
2021
Q1 		$229K Sell
2,467
-46
-2% -$4.71K 0.01% 398
2020
Q4 		$225K Sell
2,513
-1,040
-29% -$95.5K 0.01% 387
2020
Q3 		$367K Buy
+3,553
New +$383K 0.03% 271

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Ingalls & Snyder LLC's EBS Position: Q3 2021 in Review

Ingalls & Snyder LLC sold out of Emergent Biosolutions (EBS) in Q3 2021, closing a stake of 3,369 shares — an estimated $212K sold.

Ingalls & Snyder LLC first reported a position in EBS in Q3 2020 and held it in 4 quarters. The position peaked at $367K in Q3 2020. 277 funds tracked by Wall St. Rank hold EBS as of Q3 2021.

  • Ingalls & Snyder LLC reported no remaining Emergent Biosolutions position as of Q3 2021 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 3,369 Emergent Biosolutions shares in Q3 2021, an estimated $212K.
  • Ingalls & Snyder LLC first reported a position in Emergent Biosolutions in Q3 2020 and held it in 4 quarters.
  • Ingalls & Snyder LLC's Emergent Biosolutions position peaked at $367K in Q3 2020.
  • 277 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2021.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2021, filed 27 Oct 2021.